Inflammation-Based Prognostic Scores: Utility in Prognostication and Patient Selection for Cytoreduction and Perioperative Intraperitoneal Chemotherapy in Patients with Peritoneal Metastasis of Colonic Origin

Ann Surg Oncol. 2017 Apr;24(4):884-889. doi: 10.1245/s10434-016-5693-2. Epub 2016 Nov 28.

Abstract

Background: Tumor-associated systemic inflammatory response has been correlated with prognosis. Our aim was to analyze the utility of inflammation-based prognostic scores for prognostication and patient selection for cytoreduction and perioperative intraperitoneal chemotherapy (POIC) in patients diagnosed with peritoneal metastasis of colonic origin.

Methods: A retrospective analysis of a prospectively maintained database for all patients treated for peritoneal metastasis of colonic origin from February 2001 to April 2015. Inflammation-based prognostic scores including neutrophil-lymphocyte ratio, platelet-lymphocyte ratio (PLR) and Onodera's prognostic nutritional index (ONI) were calculated.

Results: Of 123 patients, 70 (56.9%) were men and 53 (43.1%) were women. Mean age at diagnosis was 49.9 years. Significant prognosticators in univariate analysis included intraoperative peritoneal cancer index (p < 0.000), tumor marker CA19-9 (p < 0.000), PLR (p = 0.020), POIC regimen (p < 0.003), and completeness of cytoreduction (p < 0.000). Multivariate Cox analysis identified CA19-9 (hazard ratio [HR] 1.0; 95% confidence interval [CI] 1.00-1.01, p = 0.031), ONI (HR 0.86; 95% CI 0.79-0.94, p < 0.000), PLR (HR 1.0; 95% CI 0.90-1.01, p = 0.041), incompleteness of cytoreduction CC2 and CC3, and mucinous adenocarcinoma histology as significant independent prognosticators.

Conclusions: The inflammation-based prognostic scores PLR and ONI and tumor marker CA19-9 are significant prognosticators of survival. They are useful in patient selection and prognostication for cytoreductive surgery and POIC in patients with peritoneal carcinomatosis of colonic origin.

MeSH terms

  • Adenocarcinoma, Mucinous / secondary
  • Adenocarcinoma, Mucinous / therapy*
  • Adult
  • Antineoplastic Agents / administration & dosage
  • Blood Platelets*
  • CA-19-9 Antigen / blood
  • Colonic Neoplasms / pathology*
  • Cytoreduction Surgical Procedures
  • Female
  • Humans
  • Inflammation / blood
  • Infusions, Parenteral
  • Lymphocyte Count
  • Lymphocytes*
  • Male
  • Middle Aged
  • Neoplasm, Residual
  • Neutrophils*
  • Nutritional Status
  • Patient Selection*
  • Peritoneal Neoplasms / secondary*
  • Peritoneal Neoplasms / therapy*
  • Platelet Count
  • Prognosis
  • Retrospective Studies

Substances

  • Antineoplastic Agents
  • CA-19-9 Antigen